Aiforia Technologies Oyj (AIFORIA) Fair Value & Analysis
Healthcare · FI · Market cap €65.0M
Fair value as of: Jun 24, 2026
Analysis
Aiforia Technologies Oyj (AIFORIA) currently trades at €1.80, while our model-based Fair Value estimate is €2.27 — implying the stock looks roughly 26.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Aiforia Technologies Oyj, together with its subsidiary, Aiforia Inc., provides AI-based image analysis software used in clinical, preclinical, and academic laboratories to pathologists and researchers in Finland, rest of Europe, North America, and internationally. It offers tools for AI-supported diagnostics and visualization of patient samples, as well as automated screening and reporting tools for the treatment of various cancers, such as breast, lung, and prostate cancer; CE-IVD marked Aiforia clinical suite viewer for the clinical pathology workflow; and Aiforia Create, an agile solution to develop an AI model for image analysis application. The company's products are used for the treatment of Parkinson's disease, organ transplantation, and liver and inflammatory bowel diseases. The company serves academic institutes and pharmaceutical companies through direct and sales partners. Aiforia Technologies Oyj was incorporated in 2013 and is headquartered in Helsinki, Finland.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Aiforia Technologies Oyj (AIFORIA) undervalued?
What is the fair value of AIFORIA?
What is the quality score of AIFORIA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.